308 related articles for article (PubMed ID: 30102555)
1. Ovarian cancer screening-ultrasound; impact on ovarian cancer mortality.
Kamal R; Hamed S; Mansour S; Mounir Y; Abdel Sallam S
Br J Radiol; 2018 Oct; 91(1090):20170571. PubMed ID: 30102555
[TBL] [Abstract][Full Text] [Related]
2. The role of transvaginal ultrasound in screening for ovarian cancer.
Campbell S; Gentry-Maharaj A
Climacteric; 2018 Jun; 21(3):221-226. PubMed ID: 29490504
[TBL] [Abstract][Full Text] [Related]
3. Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Henderson JT; Webber EM; Sawaya GF
JAMA; 2018 Feb; 319(6):595-606. PubMed ID: 29450530
[TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial.
Buys SS; Partridge E; Greene MH; Prorok PC; Reding D; Riley TL; Hartge P; Fagerstrom RM; Ragard LR; Chia D; Izmirlian G; Fouad M; Johnson CC; Gohagan JK;
Am J Obstet Gynecol; 2005 Nov; 193(5):1630-9. PubMed ID: 16260202
[TBL] [Abstract][Full Text] [Related]
5. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.
Buys SS; Partridge E; Black A; Johnson CC; Lamerato L; Isaacs C; Reding DJ; Greenlee RT; Yokochi LA; Kessel B; Crawford ED; Church TR; Andriole GL; Weissfeld JL; Fouad MN; Chia D; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hartge P; Pinsky PF; Zhu CS; Izmirlian G; Kramer BS; Miller AB; Xu JL; Prorok PC; Gohagan JK; Berg CD;
JAMA; 2011 Jun; 305(22):2295-303. PubMed ID: 21642681
[TBL] [Abstract][Full Text] [Related]
6. Screening for ovarian cancer in the general population.
Chu CS; Rubin SC
Best Pract Res Clin Obstet Gynaecol; 2006 Apr; 20(2):307-20. PubMed ID: 16364690
[TBL] [Abstract][Full Text] [Related]
7. Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival.
Temkin SM; Miller EA; Samimi G; Berg CD; Pinsky P; Minasian L
Eur J Cancer; 2017 Dec; 87():182-188. PubMed ID: 29156299
[TBL] [Abstract][Full Text] [Related]
8. Estimating Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in the United States: Secondary Analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Moss HA; Berchuck A; Neely ML; Myers ER; Havrilesky LJ
JAMA Oncol; 2018 Feb; 4(2):190-195. PubMed ID: 29222541
[TBL] [Abstract][Full Text] [Related]
9. Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial.
Pinsky PF; Zhu C; Skates SJ; Black A; Partridge E; Buys SS; Berg CD
Int J Cancer; 2013 May; 132(9):2127-33. PubMed ID: 23065684
[TBL] [Abstract][Full Text] [Related]
10. Analysis of serial ovarian volume measurements and incidence of ovarian cancer: implications for pathogenesis.
Bodelon C; Pfeiffer RM; Buys SS; Black A; Sherman ME
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25217774
[TBL] [Abstract][Full Text] [Related]
11. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
BJOG; 2014 Dec; 121 Suppl 7():35-9. PubMed ID: 25488086
[TBL] [Abstract][Full Text] [Related]
12. Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the prostate, lung, colorectal, and ovarian screening trial.
Partridge EE; Greenlee RT; Riley TL; Commins J; Ragard L; Xu JL; Buys SS; Prorok PC; Fouad MN
Obstet Gynecol; 2013 Jan; 121(1):25-31. PubMed ID: 23262924
[TBL] [Abstract][Full Text] [Related]
13. Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
Rosenthal AN; Fraser LSM; Philpott S; Manchanda R; Burnell M; Badman P; Hadwin R; Rizzuto I; Benjamin E; Singh N; Evans DG; Eccles DM; Ryan A; Liston R; Dawnay A; Ford J; Gunu R; Mackay J; Skates SJ; Menon U; Jacobs IJ;
J Clin Oncol; 2017 May; 35(13):1411-1420. PubMed ID: 28240969
[TBL] [Abstract][Full Text] [Related]
14. Screening for ovarian cancer in the general population.
Gentry-Maharaj A; Menon U
Best Pract Res Clin Obstet Gynaecol; 2012 Apr; 26(2):243-56. PubMed ID: 22182415
[TBL] [Abstract][Full Text] [Related]
15. Recent developments in ovarian cancer screening.
Menon U; Jacobs IJ
Curr Opin Obstet Gynecol; 2000 Feb; 12(1):39-42. PubMed ID: 10752515
[TBL] [Abstract][Full Text] [Related]
16. The role of CA 125 in screening for ovarian cancer.
Rosenthal AN; Jacobs IJ
Int J Biol Markers; 1998; 13(4):216-20. PubMed ID: 10228904
[TBL] [Abstract][Full Text] [Related]
17. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.
Pinsky PF; Yu K; Kramer BS; Black A; Buys SS; Partridge E; Gohagan J; Berg CD; Prorok PC
Gynecol Oncol; 2016 Nov; 143(2):270-275. PubMed ID: 27615399
[TBL] [Abstract][Full Text] [Related]
18. Use of Biomarkers in Screening for Cancer.
Duffy MJ
Adv Exp Med Biol; 2015; 867():27-39. PubMed ID: 26530358
[TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.
Menon U; Gentry-Maharaj A; Burnell M; Singh N; Ryan A; Karpinskyj C; Carlino G; Taylor J; Massingham SK; Raikou M; Kalsi JK; Woolas R; Manchanda R; Arora R; Casey L; Dawnay A; Dobbs S; Leeson S; Mould T; Seif MW; Sharma A; Williamson K; Liu Y; Fallowfield L; McGuire AJ; Campbell S; Skates SJ; Jacobs IJ; Parmar M
Lancet; 2021 Jun; 397(10290):2182-2193. PubMed ID: 33991479
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]